Press Release / Mar 17, 2021
Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Hovione today announced the appointment of Dr. Jean-Luc Herbeaux as Hovione’s Chief Executive Officer, effective 1st April 2022
Presented by the Hénokiens Association and the Château du Clos Lucé
Safety First, Quality Always: We are continuously improving the safety of our operations with the patient’s safety in mind.
Hovione is proud to announce the opening of a state-of-the-art continuous tableting (CT) line at its R&D Center in Lisbon.